Abstract:Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. An open, controlled, 16-week study was performed with the aim of evaluating the efficacy and safety of memantine in patients with clinically diagnosed LBD (criteria of McKeith et al… Show more
“…Modified motor UPDRS analysis did not detect any significant differences within or between the previous randomization groups. In all, the results do not contradict current knowledge on memantine being well-tolerated in PDD and DLB patients (Aarsland et al, 2009;Leroi et al, 2009;Levin et al, 2009). Patients were collected from psychiatric, neurological and memory outpatient clinics in three different countries, where they had been diagnosed by experienced practitioners.…”
The findings inform clinical practice that any possible memantine-associated benefits might be rapidly lost after drug withdrawal. The magnitude of deterioration suggests a symptomatic rather than a disease-modifying effect of the drug. Open-label results should merely be considered inspiration for future trials.
“…Modified motor UPDRS analysis did not detect any significant differences within or between the previous randomization groups. In all, the results do not contradict current knowledge on memantine being well-tolerated in PDD and DLB patients (Aarsland et al, 2009;Leroi et al, 2009;Levin et al, 2009). Patients were collected from psychiatric, neurological and memory outpatient clinics in three different countries, where they had been diagnosed by experienced practitioners.…”
The findings inform clinical practice that any possible memantine-associated benefits might be rapidly lost after drug withdrawal. The magnitude of deterioration suggests a symptomatic rather than a disease-modifying effect of the drug. Open-label results should merely be considered inspiration for future trials.
“…One RDBPC studyshowed a statistically significant improvement in cognition (MMSE) while showing no significant changes in the Parkinsonian or psychotic symptoms. 45 This study suggests memantine may prove useful for DLB, but the study was short (16 weeks) subjects (n = 23). Further studies are merited to ensure the safety and efficacy of memantine in these patients.…”
Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer's disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine's safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.
“…Of the included trials, nine were RCTs 10,12,16,21,[28][29][30][31][32] , and 20 were uncontrolled single-arm trials. 11,[13][14][15][17][18][19][20][33][34][35][36][37][38][39][40][41][42][43][44]…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.